News Cardiff Oncology, Inc.

Equities

CRDF

US14147L1089

Market Closed - Nasdaq Other stock markets 04:00:02 2024-04-23 pm EDT			5-day change	1st Jan Change
4.17 ^USD	-4.36%		-9.15%	+181.76%

Apr. 08	Cardiff Oncology Presents Novel Preclinical Data At Aacr Annual Meeting 2024 That Supports Ongoing First-Line Ras-Mutated Mcrc Clinical Study	CI
Mar. 06	HC Wainwright Adjusts Price Target on Cardiff Oncology to $14 From $12, Keeps Buy Rating	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study	Apr. 08	AQ
Cardiff Oncology Presents Novel Preclinical Data At Aacr Annual Meeting 2024 That Supports Ongoing First-Line Ras-Mutated Mcrc Clinical Study	Apr. 08	CI
Thinking about buying stock in Cardiff Oncology, BIOLASE, Akebia Therapeutics, Astera Labs, or Atossa Therapeutics?	Mar. 26	PR
Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024	Mar. 06	AQ
HC Wainwright Adjusts Price Target on Cardiff Oncology to $14 From $12, Keeps Buy Rating	Mar. 06	MT
Sector Update: Health Care Stocks Rising Late Afternoon	Mar. 01	MT
Sector Update: Health Care	Mar. 01	MT
Cardiff Oncology Shares Jump, Discontinued Cancer Treatment Trial Shows Efficacy	Mar. 01	MT
Piper Sandler Adjusts Price Target on Cardiff Oncology to $7 From $5, Maintains Overweight Rating	Mar. 01	MT
Transcript : Cardiff Oncology, Inc., Q4 2023 Earnings Call, Feb 29, 2024	Feb. 29
Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update	Feb. 29	AQ
Cardiff Oncology, Inc. Announces First Patient Dosed in Randomized First-Line RAS-Mutated Metastatic Colorectal Cancer Trial (CRDF-004)	Feb. 29	CI
Cardiff Oncology, Inc. Provides Clinical Update on Phase 2 Randomized Second-Line ONSEMBLE Trial in Patients with RAS-Mutated mCRC	Feb. 29	CI
Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC	Feb. 29	AQ
Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)	Feb. 29	AQ
Cardiff Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference	Feb. 26	GL
Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference	Feb. 26	AQ
Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update	Feb. 22	GL
Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update	Feb. 22	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Cardiff Oncology, Inc.

Equities

CRDF

US14147L1089

Summary

Filters